RANTES gene mRNA expression and its -403 G/A promoter polymorphism in coronary artery disease

Gene

Volumn 487, Issue 1, 2011, Pages 103-106

  Tavakkoly Bazzaz, Javad ^a,b   Amiri, Parvin ^a   Tajmir Riahi, Mohammad ^c   Javidi, Daryoosh ^c   Khojasteh Fard, Maryam ^a,b   Taheri, Zahra ^d   Tabrizi, Aida ^a   Keramatipour, Mohammad ^b   Amoli, Mahsa M ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

403 G A polymorphism; CAD; RANTES

Indexed keywords

MESSENGER RNA; RANTES;

ADULT; ALLELE; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION;

ADULT; AGED; ALLELES; CHEMOKINE CCL5; CORONARY ARTERY DISEASE; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENOTYPE; HUMANS; LEUKOCYTES, MONONUCLEAR; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 80052323439     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2011.07.019     Document Type: Article

References (25)

1. Amoli M.M., Miranda-Filloy J.A., Vazquez-Rodriguez T.R., Ollier W.E., Gonzalez-Gay M.A. Regulated upon activation normal T-cell expressed and secreted (RANTES) and epithelial cell-derived neutrophil-activating peptide (ENA-78) gene polymorphisms in patients with biopsy-proven erythema nodosum. Clin. Exp. Rheumatol. 2009, 27(1 Suppl. 52):S142-S143.
2. Antonopoulos S. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
3. Appay V., Rowland-Jones S.L. RANTES: a versatile and controversial chemokine. Trends Immunol. 2001, 22:83-87.
4. Aukrust P., et al. Chemokines and cardiovascular risk. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1909-1919.
5. Cushing S.D., et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:5134-5138.
6. Donlon T.A., Krensky A.M., Wallace M.R., Collins F.S., Lovett M., Clayberger C. Localization of a human T-cell-specific gene, RANTES (D17S136E), to chromosome 17q11.2-q12. Genomics 1990, 6:548-553.
7. Fryer A.A., et al. The -403 G->A promoter polymorphism in the RANTES gene is associated with atopy and asthma. Genes Immun. 2000, 1:509-514.
8. Genuth S., et al. Expert committee on the diagnosis and classification of diabetes mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003, 26:3160-3167.
9. Hajeer A.H., al Sharif F., Ollier W.E. A polymorphism at position -403 in the human RANTES promoter. Eur. J. Immunogenet. 1999, 26:375-376.
10. Hansson G.K. Immune mechanisms in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2001, 21:1876-1890.
11. Jang Y., et al. The RANTES -403 G>A promoter polymorphism in Korean men: association with serum RANTES concentration and coronary artery disease. Clin. Sci. (Lond.) 2007, 113:349-356.
12. McDermott D.H., et al. Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS Cohort Study. AIDS 2000, 14:2671-2678.
13. Nakajima K., et al. RANTES promoter genotype is associated with diabetic nephropathy in type 2 diabetic subjects. Diabetes Care 2003, 26:892-898.
14. Nickel R.G., et al. Atopic dermatitis is associated with a functional mutation in the promoter of the C-C chemokine RANTES. J. Immunol. 2000, 164:1612-1616.
15. Pattison J.M., Nelson P.J., Huie P., Sibley R.K., Krensky A.M. RANTES chemokine expression in transplant-associated accelerated atherosclerosis. J. Heart Lung Transplant. 1996, 15:1194-1199.
16. Reape T.J., Groot P.H. Chemokines and atherosclerosis. Atherosclerosis 1999, 147:213-225.
17. Rose G., Blackburn H. WHO Monograph Series: Cardiovascular Survey Methods 1982, World Health Org., Geneva.
18. Rothenbacher D., Muller-Scholze S., Herder C., Koenig W., Kolb H. Differential expression of chemokines, risk of stable coronary heart disease, and orrelation with established cardiovascular risk markers. Arterioscler. Thromb. Vasc. Biol. 2006, 26:194-199.
19. Schall T.J. Biology of the RANTES/SIS cytokine family. Cytokine 1991, 3:165-183.
20. Simeoni E., et al. Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosis. Eur. Heart J. 2004, 25:1438-1446.
21. Tereshchenko I.P., et al. CCL5/RANTES gene polymorphisms in Slavonic patients with myocardial infarction. Mediators Inflamm. 2011, 2011:29.
22. Terkeltaub R., Banka C.L., Solan J., Santoro D., Brand K., Curtiss L.K. Oxidized LDL induces monocytic cell expression of interleukin-8, a chemokine with T-lymphocyte chemotactic activity. Arterioscler. Thromb. 1994, 14:47-53.
23. Veillard N.R., et al. Antagonism of RANTES receptors reduces atherosclerotic plaque formation in mice. Circ. Res. 2004, 94:253-261.
24. Vogiatzi K., et al. Genetic diversity of RANTES gene promoter and susceptibility to coronary artery disease and restenosis after percutaneous coronary intervention. Thromb. Res. 2009, 124:84-89.
25. Wilcox J.N., Nelken N.A., Coughlin S.R., Gordon D., Schall T.J. Local expression of inflammatory cytokines in human atherosclerotic plaques. J. Atheroscler. Thromb. 1994, (Suppl. 1):S10-S13.